Mirtazapine in Major Depression With Comorbid Generalized Anxiety Disorder
about
Inhibition of stress- or anxiogenic-drug-induced increases in dopamine release in the rat prefrontal cortex by long-term treatment with antidepressant drugs.A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study.Considerations in the management of the patient with comorbid depression and anxiety.Mirtazapine: only for depression?Does use of tetracyclic antidepressant-mirtazapine reduce cancer risk in depression patients?Chronic treatment with imipramine or mirtazapine antagonizes stress- and FG7142-induced increase in cortical norepinephrine output in freely moving rats.Inhibition by venlafaxine of the increase in norepinephrine output in rat prefrontal cortex elicited by acute stress or by the anxiogenic drug FG 7142.Massive weight gain and hostility force mirtazapine stoppage.Functional dyspepsia and mirtazapine.Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.Pharmacotherapeutic options in the treatment of comorbid depression and anxiety.The in vitro genotoxic and cytotoxic effects of remeron on human peripheral blood lymphocytes.A Review of the Pharmacological and Clinical Profile of MirtazapineHighly Sensitive Micellar Enhanced Spectrofluorimetric Method for Determination of Mirtazapine in Tablets and Human Urine: Application to In Vitro Drug Release and Content Uniformity Test
P2860
Q31962157-C88343EB-66D1-49F1-B4BF-7BD7930C46AEQ34183517-0827A356-FC55-4335-AAED-EC97D5A5B2B0Q34560858-D4550979-44BE-4C1E-9166-4868F4D84F4DQ35076173-F917AAF7-3997-4C3C-9F38-A311B26753D5Q38779530-F473A11C-6276-4042-9303-BFA16784DB92Q39334973-DE5D8242-9D22-451A-BDD7-6E8C13F5ECBFQ43825642-AD014BC4-3E06-4D03-BB51-FF53FA71D5D9Q44048458-9D8B3C36-BE2E-4BA5-833B-52168A9AD0ECQ44125654-D21C8BA4-8542-4476-9E48-EDFAFAD361B3Q44125657-8C32C159-491E-402B-B0CA-91DA4496A08DQ48912488-FA57821B-FDB7-4BD1-9CE2-83C067BBA045Q51902879-03630262-496F-4BB8-8E48-17B2536D2374Q53025226-375D5BF4-7070-4E6D-AA61-0C7894B334CDQ56016663-EF363CB2-051F-4C29-912D-368BE6884DCEQ59125559-053FAAC4-E888-44F4-9BDD-DFDE1AD0E12F
P2860
Mirtazapine in Major Depression With Comorbid Generalized Anxiety Disorder
description
im Juli 1999 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 1999
@uk
name
Mirtazapine in Major Depression With Comorbid Generalized Anxiety Disorder
@en
Mirtazapine in Major Depression With Comorbid Generalized Anxiety Disorder
@nl
type
label
Mirtazapine in Major Depression With Comorbid Generalized Anxiety Disorder
@en
Mirtazapine in Major Depression With Comorbid Generalized Anxiety Disorder
@nl
prefLabel
Mirtazapine in Major Depression With Comorbid Generalized Anxiety Disorder
@en
Mirtazapine in Major Depression With Comorbid Generalized Anxiety Disorder
@nl
P2093
P356
P1476
Mirtazapine in Major Depression With Comorbid Generalized Anxiety Disorder
@en
P2093
Alina Puig
Blanche V. Freund
C. Lindsay DeVane
Paul J. Goodnick
P304
P356
10.4088/JCP.V60N0705
P577
1999-07-15T00:00:00Z